Clinical Trials

MainTitle

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push"

This study is currently recruiting participants. (see Contacts and Locations)

Verified March 2020 by TaiMed Biologics Inc.

Sponsor
TaiMed Biologics Inc.

Collaborator
Westat

Information provided by (Responsible Party)
TaiMed Biologics Inc.
ClinicalTrials.gov Identifier
NCT03913195

First received: April 9, 2019
Last updated: May 7, 2020
Last Verified: March 2020
History of Changes
Purpose

Purpose

This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push". An initial "Sentinel Group" of 5 participants will begin receiving 800mg Trogarzo on a gradual schedule of increasing concentration and decreasing administration time until undiluted IV Push over 30 seconds is achieved, while safety and pharmacokinetics are evaluated. If no safety signals are seen, the Core Group of 15 participants will be enrolled. The Core Group will receive 800mg Trogarzo via undiluted IV Push over 30 seconds while safety and pharmacokinetics are monitored.

Condition Intervention Phase
HIV-1-infection

Drug : ibalizumab-uiyk
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" Over a Reduced Interval in Clinically Stable HIV-1 Infected Trogarzo™ Experienced Patients

Further study details as provided by TaiMed Biologics Inc.:

Primary Outcome Measures

  • Safety of Trogarzo given as IV Push over 30 seconds in Sentinel Group [ Time Frame: 12 weeks ]
    Percent of subjects in Sentinel Group who complete 100% of all Trogarzo administrations given as infusion/bolus/push as per protocol
  • Safety of Trogarzo given as IV Push over 30 seconds in Core Group [ Time Frame: 10 weeks ]
    Percent of subjects in Core Group who complete 100% of all Trogarzo administrations given as infusion/bolus/push as per protocol
  • Pharmacokinetics(1) of Trogarzo infusion versus IV Push in Sentinel Group [ Time Frame: Day 1 infusion versus Day 85 IV Push ]
    Ratio of Area Under the Curve of Serum levels of Trogarzo given by 15 minute infusion versus Area Under the Curve of Serum levels of Trogarzo given by IV Push over 30 seconds
  • Pharmacokinetics(2) of Trogarzo infusion versus IV Push in Sentinel Group [ Time Frame: Day 1 infusion versus Day 85 IV Push ]
    Ratio of Trough Serum levels of Trogarzo given by 15 minute infusion versus Trough Serum levels of Trogarzo given by IV Push over 30 seconds
  • Pharmacokinetics(1) of Trogarzo infusion versus IV Push in Core Group [ Time Frame: Day 1 infusion versus Day 71 IV Push ]
    Ratio of Area Under the Curve of Serum levels of Trogarzo given by 15 minute infusion versus Area Under the Curve of Serum levels of Trogarzo given by IV Push over 30 seconds
  • Pharmacokinetics(2) of Trogarzo infusion versus IV Push in Core Group [ Time Frame: Day 1 infusion versus Day 71 IV Push ]
    Ratio of Trough Serum levels of Trogarzo given by 15 minute infusion versus Trough Serum levels of Trogarzo given by IV Push over 30 seconds
Secondary Outcome Measures:
  • Percent of subjects in the Sentinel Group who fail to maintain virologic control [ Time Frame: 99 days ]
    Percent of subjects in the Sentinel group who experience a sustained increase in log HIV-1 RNA levels of greater than 0.5log from baseline
  • Percent of subjects in the Core Group who fail to maintain virologic control [ Time Frame: 84 days ]
    Percent of subjects in the Core group who experience a sustained increase in log HIV-1 RNA levels of greater than 0.5log from baseline

Estimated Enrollment: 20
Study Start Date: May 30, 2019
Estimated Study Completion Date: May 15, 2020
Estimated Primary Completion Date: May 15, 2020 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Sentinel Group
Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
Drug: ibalizumab-uiyk

Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.

Other Name: Trogarzo
Experimental: Core Group
Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
Drug: ibalizumab-uiyk

Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.

Other Name: Trogarzo

Detailed Description:

This goal of this Phase 3 is to evaluate the safety and pharmacokinetics of administering Trogarz 800 mg once every two weeks as an undiluted IV Push over 30 seconds in clinically stable HIV-1 infected patients currently receiving treatment with a stable Trogarz-containing regimen.
The first five (5) patients enrolled will comprise the Sentinel Group. Patients six (6) through twenty (20) (the Core Group) will not be screened until the Sentinel Group has completed Day 99 (14 weeks) of the study and the DSMB has reviewed the data accumulated and given approval for enrollment of the Core Group to proceed.
The Sentinel Group will receive 2 successive doses of Trogarzo in accordance with the prescribing information. Safety and pharmacokinetic data from these administrations will serve as the comparator for each study participant. Beginning at Day 29 and continuing through Day 85, Sentinel Group participants will begin receiving the prescribed dosage of Trogarzo once every two weeks through Day 85 of the study on a schedule of increasing drug concentration and decreasing administration time at each visit to achieve an undiluted IV Push administration of Trogarzo over 30 seconds.
After review of data from the Sentinel Group by a DSMB, if approved the study will continue with enrollment of the Core Group. The Core Group will receive 2 successive doses of Trogarzo in accordance with the prescribing information. Safety and pharmacokinetic data from these administrations will serve as the comparator for each study participant. Thereafter, Core Group participants will receive the prescribed dosage of Trogarzo via undiluted IV Push over 30 seconds through Day 71 of the study.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  1. Are capable of understanding and have voluntarily signed the informed consent document
  2. Currently receiving a stable Trogarzo-containing ARV regimen for a minimum of 3 months, and no change in background ARVs anticipated over the period of study participation; a stable regimen is defined as having no changes in dose or frequency and no interruptions greater than or equal to 2 weeks during the 3 month period
  3. Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months before Screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to HIV
  4. Are able and willing to comply with all protocol requirements and procedures
  5. Are 18 years of age or older
  6. Have a life expectancy that is >6 months.
  7. Have a viral load <1,000 copies/mL at Screening
  8. CD4+ T-cell count > 50 cells/mm3 at Screening

  • Exclusion Criteria:
  • Any active AIDS-defining illness according to the Centers for Disease Control and Prevention (CDC) Revised Surveillance Case Definitions for HIV Infection 2008 (MMWR Vol.57/No. RR-10, Appendix A), or history of the same during the 3 months preceding Screening, with the following exceptions: cutaneous Kaposi's sarcoma and wasting syndrome due to HIV
  • Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study
  • Any significant acute illness within 1 week before the initial administration of study drug
  • Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be eligible for the study.
  • Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 12 weeks before Enrollment
  • Any vaccination within 7 days before Day 1
  • Any female patient who either is pregnant, intends to become pregnant, or is currently breastfeeding
  • Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations
  • Any radiation therapy during the 28 days before first administration of study medication
  • Any Grade 3 or 4 laboratory abnormality according to the Division of AIDS grading scale, except for the following asymptomatic Grade 3 events:
    • triglyceride elevation
    • total cholesterol elevation any Grade 3 or 4 reduction in CD4+ T cell counts

    contacts and locations

    Contacts and Locations

    Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

    Please refer to this study by its ClinicalTrials.gov identifier: NCT03913195

    Contacts

    Contact:   Susan Denton 407-699-0540 susandenton@westat.com
    Contact:   Christine Anderson, PhD 713-353-7911 christineanderson@westat.com

    Locations

    United States, California
    Anthony Mills MD Inc. Recruiting
    Los Angeles, California, United States, 90069
    Contact: Joey Fragoso    310-550-2271    joey.fragoso@millsclinicalresearch.com
    Contact: Ron Knight    310.550.2271    ron@tonymillsmd.com
    Principal Investigator: Tony Mills, MD
    United States, Florida
    Gary Richmond MD, PA Recruiting
    Fort Lauderdale, Florida, United States, 33316
    Contact: Vernon Appleby, RN    954-524-2550 ext 211    vfappleby@earthlink.net
    Principal Investigator: Gary Richmond, MD
    Orlando Immunology Center Recruiting
    Orlando, Florida, United States, 32803
    Contact: Janiza Veloz    407-409-7125    jveloz@oicorlando.com
    Contact: Jeffrey Dinsmore    407-647-3960 x2118    jdinsmore@oicorlando.com
    Principal Investigator: Edwin DeJesus, MD
    United States, Texas
    North Texas Infectious Disease Consultants Recruiting
    Dallas, Texas, United States, 75246
    Contact: Elisha Thomas    214-276-5646    elisha.thomas@ntidc.org
    Contact: Jessica Caldwell    214-247-4114    jessica.caldwell@ntidc.org
    Principal Investigator: Mezgebe Berhe, MD

    Sponsors and Collaborators

    TaiMed Biologics Inc.
    Westat

    Investigators

    Study Chair: Martin Markowitz, MD TaiMed Biologics Inc. - Consultant
    More Information

    More Information


    Responsible Party: TaiMed Biologics Inc.  
    ClinicalTrials.gov Identifier: NCT03913195   History of Changes  
    Other Study ID Numbers: TMB-302  
    Study First Received: April 9, 2019  
    Last Updated: May 7, 2020  
    Individual Participant Data    
    Plan to Share IPD: No  

    Studies a U.S. FDA-regulated Drug Product: Yes  
    Studies a U.S. FDA-regulated Device Product: No  

    Keywords provided by TaiMed Biologics Inc.:

    HIV
    ibalizumab
    MDR HIV

    Additional relevant MeSH terms:
    Ibalizumab

    ClinicalTrials.gov processed this data on June 02, 2020
    This information is provided by ClinicalTrials.gov.